Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor model based on the published strategy ...

The U.S. Food & Drug Administration has approved Johnson & Johnson's device for a type of condition which causes abnormal ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) today and set a price target of $169.00. The company’s shares closed yesterday at ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor model based on the published strategy ...

RBC Capital analyst Shagun Singh Chadha reiterated a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target of $181.00. The company’s shares closed yesterday ...

Johnson & Johnson shares initially rose Tuesday after the drugmaker reported better-than-expected third-quarter sales and raised full-year revenue guidance. However, the stock pulled back and was ...

Johnson & Johnson stock (NYSE: JNJ) will report its Q3 2024 results on Tuesday, October 15. We expect the company to post revenue of $22.2 billion and earnings of $2.20 per share, broadly aligning ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other most profitable cheap stocks to invest in. Sherry Paul, Morgan Stanley Private Wealth ...

On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating the consensus of $2.21. The pharmaceutical giant reported sales of $22.47 ...